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Background & Aims: Chronic hepatitis B virus (HBV) infection is characterized by 
the presence of defective viral envelope proteins (hepatitis B surface antigen, HBsAg) 
and the duration of infection – most patients acquire the infection at birth or during the 
first years of life. We investigated the effects of these two factors on patients’ global 
lymphocytes and HBV-specific T cells.  
Methods: We collected blood samples and clinical data from 243 HBV-infected 
patients of different age (3 – 75 y) and of various ethnicities in the United Kingdom 
and the People’s Republic of China. We measured virological (HBV DNA, HBV 
genotype, HBsAg, HBeAg) and clinical parameters (ALT) and isolated peripheral 
blood mononuclear cells (PBMC). In 48 chronically infected patients with varying 
levels of serum HBsAg we analyzed global T- and natural killer (NK)-cell expression 
of 40 markers by mass cytometry. PBMC of 189 chronically infected and 38 patients 
with resolved infection were incubated with overlapping HBV-peptide libraries to 
identify HBV-specific T cells by interferon gamma ELISpot assays or by flow 
cytometry. To analyze which covariates are associated with HBV-specific T cell 
responses, we fit a multivariate linear regression model and performed variable 
selection using Akaike's Information Criterion (AIC).  
Results: Although global T and NK cell phenotypes and functions did not change with 
level of serum HBsAg, numbers of HBs-specific T cells were positively correlated with 
serum levels of HBsAg (r=0.3367; P<.00001). However, after performing variable 
selection using AIC, the final multivariate linear regression model identified the age of 
the patients as the only significant covariate associated with numbers of HBs-specific 
T cells (P=.000115). In patients younger than 30 y, HBs-specific T cells constituted 
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28.26% of the total HBV-specific T cells; this value decreased to 7.14% in patients 
older than 30 y.  
Conclusions: In an analysis of immune cells from patients with chronic HBV infection, 
we found the duration of HBsAg exposure, rather than the absolute quantity of HBsAg, 
alters the profile of HBV-specific T cell responses. Although the presence of HBs-
specific T cells might not be essential for the clearance of HBV infection in all patients, 
our study indicates that therapeutic intervention designed to restore anti-HBV 
immunity should consider patients younger than 30 y. 
 




An estimated 250 million people worldwide are infected with HBV, a non-cytopathic 
hepatotropic DNA virus resulting in nearly 1 million deaths per year from the 
complications of chronic hepatitis1. A peculiar feature of HBV is its ability to produce 
not only a progeny of infectious virions, but also truncated forms of the nucleocapsid 
protein (HBeAg) and defective non-infectious particles comprised of different forms of 
surface proteins (HBsAg)2. These non-infectious viral proteins (HBeAg and HBsAg) 
are secreted into the serum and have been shown to impact HBV host immunity. For 
example, HBeAg has been shown, in animal models,  to play a role in the suppression 
of nucleocapsid-specific T cells in vertically HBV-infected new-borns3,4. 
 
The defective particles made by surface proteins (~1014/ml) may have a broader effect 
on patients’ immune cells. It is likely that they act primarily as a decoy for protective 
anti-HBs antibodies, since they outnumber the infectious virions 103 to 106-fold and 
are collectively measured in patients’ sera as HBsAg in concentrations that can 
exceed 10-20 µg/ml (~10,000 IU/ml)5. Besides, HBsAg is associated with functional 
defects of HBs-specific B cells6,7, and may also have an impact on HBV-specific T 
cells. Antigens presented by hepatocytes modulate the priming of T cells8 and the 
continuous stimulation by antigens presented by both hepatocytes and professional 
antigen presenting cells could exhaust and subsequently delete T cells. This seems 
to occur in HBV-transgenic mice9 and recent detailed analysis of HBV-specific T cells 
in adult patients with chronic hepatitis B (CHB) showed a preferential detection of core- 
and polymerase-specific T cells, but seldom HBs-specific T cells10-12. HBsAg has also 
been suggested to have an impact on innate immune responses13, especially on 
dendritic cell function14, although this last hypothesis has not been confirmed by other 
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data15.These lines of evidence have generated the hypothesis that HBsAg has a 
generic immunosuppressive activity and a therapeutic reduction of quantitative HBsAg 
(qHBsAg) is a necessary step to restore HBV-specific immune responses and to reach 
functional cure16. This idea has garnered great popularity and therapeutic efforts to 
reduce HBsAg have led to the development of compounds with the ability to inhibit 
HBsAg production17,18, despite the fact that a direct proportional relationship between 
immunological defects and qHBsAg has never been demonstrated; moreover only 
complete HBsAg loss is associated with recovery of HBV-specific T and B cell 
responses6,19. 
 
A robust understanding of the duration of HBsAg exposure and its impact on anti-HBV 
host cellular immunity is also lacking. This is surprising given that CHB infection is 
typically acquired at birth and the lifelong persistence of high quantities of HBV 
antigens is a peculiar trait of CHB infection5. Moreover, evidence from animal models 
showed that duration of viral antigen exposure progressively deletes antiviral T cells20. 
This could be explained by the general consensus that an awakening of the patients’ 
immune response against HBV was only present in adulthood (immune active phase). 
However, the demonstration that HBV-specific immune responses21 and the 
pathological consequences of CHB22 are already detectable in young patients with 
chronic infection, provide the rationale to analyse both the effect of HBV antigen 





Material and Methods 
Study approval: Clinical assessment and peripheral blood sampling was performed 
at the Royal London Hospital (London, UK) and at the Third Affiliated Hospital of Sun 
Yat-sen University (Guangzhou, China), in accordance with the Declaration of 
Helsinki. Written informed consent was obtained, and the study was approved by the 
London Harrow Research Ethics Committee (reference 10/H0715/239), the East 
London & The City Research Ethics Committee (reference P/01/023) and the Clinical 
Trial Research Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen 
University (reference [2015]2-206). 
 
Patients: 205 patients with chronic HBV infection were selected for this study. 
Furthermore, 27 individuals with resolved acute HBV (anti-HBc positive and anti-HBs 
positive), and 11 patients with a clinical history of resolved chronic HBV infection were 
included. Figure 1 and Tables 1 and 2 summarize the clinical and virological 
parameters of all patients. 
 
Clinical and virological parameters: On enrolment, viral serology and HBV DNA 
levels were tested in all patients (COBAS AmpliPrep/COBAS TaqMan HBV test v2.0; 
Roche Molecular Diagnostics). HBsAg, HBeAg, and anti-HBe levels were measured 
with the chemiluminescent microparticle immunoassay (CMIA; Abbott Architect, 
Abbott Diagnostics), and HBV genotype was recorded where available. All patients 
included were HCV, HDV and HIV negative. 
 





Staining for CyTOF: To avoid possible batch effects from running multiple 
experiments, PBMCs of all 48 CHB patients were only divided into 2 sets of 24; thawed 
and stained at the same time. Cells were washed and each sample was divided to 
perform 2 assays; either stained directly or stimulated for 4 hours with phorbol-12-
myristate-13-acetate (PMA; 150 ng/ml) and ionomycin (1 μM) in the presence of 
brefeldin A and monensin (eBioscience). Staining for cell viability, surface and 
intracellular makers with metal tagged antibodies (Table S1), as well as sample 
labelling with dual mass-tag cellular barcodes and DNA staining were performed as 
described in detail previously23. As only a limited number of samples can be acquired 
on the same day, stained samples were frozen in 3 batches to be thawed and acquired 
over the subsequent weeks as described in detail previously23. For each batch, the 
same internal control PBMCs of a healthy donor were included as well as 8 
experimental samples (equal distribution of CHB patients with high and low HBsAg 
level, HBeAg positive/negative and treatment naïve/nucleos(t)ide-analogue [NA] 
therapy). On the day of mass cytometry acquisition, on a CyTOF2 instrument, one 
batch of stained cells was thawed at room temperature, washed, diluted and mixed 
with EQ Four Element Calibration Beads (Fluidigm). 
 
CyTOF data analysis: After acquisition, parameters were normalized with EQ beads 
(Fluidigm) and 0 values were randomized using a uniform distribution of values 
between –1 and 0 in an R script. Cells were manually de-barcoded using FlowJo 
version 10 (BD). Live lymphocytes from all samples were down-sampled to 100,000 
events to normalize the contribution between donors. High-dimensional data analysis 
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was performed with the nonlinear dimensionality reduction technique Uniform Manifold 
Approximation and Projection (UMAP)24 and FlowJo.  
 
Flow cytometry: PBMCs were thawed and stained for live cells followed by surface 
staining for 30 minutes on ice. For global T cell analysis, cells were then permeabilized 
with FoxP3 staining kit and stained for intracellular markers. All antibodies are listed 
in Table S2. Cells were acquired on an LSR-Fortessa cytometer (BD) and analysed 
with FlowJo version 10 (BD). 
 
HBV peptide libraries: Libraries of 313 fifteen-mer peptides overlapping by 10 amino 
acids were used to identify HBV-specific T cells. The peptides covered the whole 
proteome of HBV genotypes B, C, and D (GenBank AF121243, AF 112063, AF 21241, 
respectively) and were purchased from Mimotopes. Their purity was above 80%, and 
their composition was confirmed by mass spectrometry. Peptides were pooled as 
described previously25. The peptide libraries were matched to the closest HBV 
genotype of each patient, as indicated in Table 2.  
 
T cell culture: For the in vitro assays, T cell lines were generated as follows: 20% of 
PBMCs were pulsed with 10 μg/ml of each of the overlapping HBV peptides for 1 hour 
at 37°C, subsequently washed, and co-cultured with the remaining cells in AIM-V 
medium supplemented with 2% AB human serum (both Gibco; Thermo Fisher 
Scientific). T cell lines were cultured for 10 days in the presence of 20 U/ml of 




ELISpot: ELISpot assays for the detection of IFNγ–producing cells were performed 
on in vitro-expanded T cell lines using HBV peptides pooled into the following mixtures: 
X, core, envelope 1 and 2, polymerase 1, 2, 3 and 4. T cell lines were incubated 
overnight at 37°C with pools of HBV peptides (5 μg/ml of each peptide), where final 
DMSO concentrations did not exceed 0.5%. IFNγ ELISpot assays (Millipore) were 
performed as described previously25. 
 
Intracellular cytokine staining: Expanded T cell lines were stimulated overnight at 
37ºC with or without HBV peptide pools (5 μg/ml of each peptide), in the presence of 
2 μg/ml Brefeldin A (Sigma-Aldrich). As a positive control, cells were stimulated with 
PMA (2 ng/ml) and ionomycin (1 μg/ml). Cells were stained with the LIVE/DEAD fixable 
far red dead cell stain kit (ThermoFisher) and surface antibodies (Table S3). Cells 
were subsequently fixed and permeabilized using the Cytofix/Cytoperm kit (BD 
Pharmingen), stained with intracellular antibodies (Table S3), acquired on an LSR-
Fortessa cytometer (BD) and analysed with FlowJo version 10 (BD). 
 
Multivariate analysis: To analyse which covariates are associated with HBs-specific 
T cell responses, we fit a multivariate linear regression model and performed variable 
selection using Akaike's Information Criterion (AIC). T cell responses have been 
transformed as log(SFU+1) to make the distribution of the response closer to the 
Normal. We included a set of 9 potential covariates in the model: Gender, HBeAg, 
Age, HBsAg, HBV-DNA and ALT, as well as the interactions between Age and HBeAg, 




Statistical Analysis: Statistical significance was determined by GraphPad Prism 





Patient selection and experimental procedures. 
We selected 243 HBV-infected patients. Global circulating T and NK cells were studied 
in 48 patients (Table 1), while HBV-specific T cells were analysed in 189 patients with 
CHB (HBsAg+) and in 38 patients with resolved infection (anti-HBs+; 27 after acute 
HBV infection, 11 following documented CHB infection; Table 2). Figure 1A depicts 
the number of individuals who were studied with different immunological techniques. 
CHB patients were characterized by a wide range of qHBsAg (negative to 106 IU/ml) 
with a preponderance of levels between 103 and 105 IU/ml. A broad age distribution 
was represented (3 to 75 years), with a median age of 29. Notably, our study included 
a considerable number of patients above 50 years of age (n=30) and equally a 
sizeable number of under 20-year-olds (n=34). As expected5, HBsAg levels declined 
with age (Fig 1B). In accordance with the natural profile of HBV infection, CHB patients 
with HBeAg positive chronic infection (n=34) or chronic hepatitis (n=47) were younger 
(median age 24) than patients classified with HBeAg negative chronic infection (n=35; 
median age 25) or chronic hepatitis (n=89; median age 44; Fig 1C). The CHB cohort 
was comprised of patients with no (alanine aminotransferase [ALT] <40 IU/mL), mild 
(ALT 40-80 IU/mL) and severe (ALT >80 IU/mL) hepatitis equally distributed across 
age (Fig 1D).  
 
The impact of HBsAg quantity on global T and NK cells. 
We first analysed the impact of varying levels of HBsAg on global non-antigen-specific 
T and NK cells. Forty-eight patients with CHB infection were selected based on their 
serum qHBsAg (2 to 365,623 IU/ml). Equal numbers of HBeAg positive and negative 
patients were represented, including treatment-naïve patients and those undergoing 
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NA therapy (Table 1). CyTOF technology was utilized to simultaneously analyse their 
PBMCs for the expression of 40 markers (Table S1) involved in T and NK cell 
activation, differentiation, exhaustion, in addition to the production of different 
cytokines and cytotoxicity-associated molecules, both spontaneously and following 
stimulation.  
 
CyTOF data were analysed with the high-dimensionality reduction algorithm UMAP, 
which maps cells with related phenotypes in close proximity, and thus automatically 
separated all major lymphocyte subsets24 (Fig 2A, S1A). UMAP density plots (Fig 2B) 
and gated lymphocyte subsets (Fig S1B) displayed no difference in the frequencies 
of CD4 and CD8 T cells of naïve, memory and effector phenotypes; similarly, no 
difference in MAIT, NK, B and mononuclear phagocyte cell subsets was detected in 
CHB patients with varying levels of HBsAg. Figure 2C shows the median expression 
level of 33 markers in 20 different lymphocyte subsets in patients with low (<1,000 
IU/ml; n=14) and high (>10,000 IU/ml; n=13) levels of HBsAg; notably no significant 
difference was observed. Also, applying correlation analysis of all markers in all 
subsets with qHBsAg, we did not find any association (data not shown).  
 
Moreover, the production of different cytokines and cytotoxicity-associated molecules 
was not altered by qHBsAg in different T and NK cell subsets (Fig 2D, 2F), and no 
correlation with the expression of several immunoregulatory receptors was identified26, 
including PD-1, CTLA-4, TIM-3, KLRG1 and CD160 (Fig 2E). To confirm that qHBsAg 
is not affecting global T cell exhaustion or inhibition, we analysed regulatory T cell 
frequency (CD4+FoxP3+CD25+) and additional immunoregulatory receptors, including 
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BTLA and TIGIT, by flow cytometry. Similarly, these markers did not correlate with 
qHBsAg (Fig S1C). 
 
Comparative analysis of the T and NK cell features was performed either by 
considering only qHBsAg as a distinct parameter among all the 48 CHB patients or by 
separating the patients based on HBeAg and/or NA-treatment status, which 
importantly did not reveal any significant correlation (data not shown). However, our 
method was able to identify phenotypic alterations in immune cell subsets that are 
known to be associated with age, serving as an internal positive control (Fig S1D). 
Taken together, these data show that qHBsAg does not impact any generic 
immunomodulatory function on T and NK cells. 
 
The impact of HBsAg quantity and patient age on HBV-specific T cells. 
Having analysed the effect of HBsAg on global T and NK cells, we studied the impact 
of qHBsAg and patients’ age on HBV-specific T cells in terms of frequency and fine-
specificity. We stimulated PBMCs of 189 CHB patients with a pool of overlapping 
peptides covering the whole HBV proteome, using peptide libraries matching the HBV 
genotype of each patient. After 10 days of in-vitro expansion, the ability of T cells to 
produce IFNγ following stimulation with distinct peptide pools covering single HBV 
proteins (envelope, core, polymerase and X; HBs, HBc, HBpol and HBx respectively) 
was tested using ELISpot assays (Fig 1A).  
 
We first quantified HBV-specific T cells in CHB patients classified according to the 
nomenclature defined in the EASL 2017 clinical practice guidelines (CPG), as shown 
in Figure 3A. No significant differences were detected on total HBV-specific T cells. 
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Yet, we found significantly more HBs-specific T cells in patients with HBeAg positive 
chronic infection versus HBeAg negative chronic hepatitis, and a trend towards an 
increase in the quantity of HBcore-specific T cells in HBeAg negative CHB patients. A 
previous study of HBV-specific T cells in adult CHB patients27 similarly showed an 
increased HBcore-specific T cell response in HBeAg negative patients, but did not 
reveal any significant association of HBs-specific T cells with CHB disease phase. 
However, distinct from the study by Park et al.27, our patient population includes a 
broader age-range and is not restricted to adult patients (Fig 1B, 1D). We then directly 
correlated the quantity of HBV-specific T cells with qHBsAg (Fig 3B) and age (Fig 
3C). The quantity of T cells specific to the whole HBV proteome did not show any 
significant correlation (Fig 3B, 3C). However, when we decipher T cells specific to the 
individual proteins, the magnitude of HBc-, HBpol- and HBx-specific T cells appeared 
unaffected (Fig 3D), whereas the quantity of HBs-specific T cells correlated positively 
with HBsAg levels (Fig 3B) and negatively with increasing age (Fig 3C). Importantly, 
after performing variable selection using AIC, the final multivariate linear regression 
model (described in Material and Methods) identified the age of the patients as the 
only significant covariate associated with numbers of HBs-specific T cells (P = 
0.000115; Table S4). Quantity of HBs-, HBc-, HBpol- and HBx-specific T cells in 
individual CHB patients is displayed in Figure 3D. While HBc-, HBpol- and HBx-
specific T cell responses were uniformly distributed across age, robust HBs-specific T 
cell responses were detectable almost exclusively in the first three decades of infection 
(Fig 3D), when CHB patients displayed high qHBsAg (Fig 1B). Intracellular cytokine 
staining of CD4 and CD8 T cells in CHB patients with an ELISpot response to HBs-
peptides showed that such responses were mediated by both CD4 (11/20) and/or CD8 
(13/20) T cells (Fig S2).  
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Remarkably, a reduction of HBs-specific T cells was observed in patients over the age 
of 30, despite a greater number of patients in this group being treated with NA therapy 
(Table 2). This is at odds with the concept that NA therapy should induce partial 
recovery of HBV-specific T cell responses28. Importantly, HBV-specific T cells were 
not increased in CHB patients with liver inflammation; on the contrary, we observed a 
trend towards a negative association with ALT levels, which reached significance for 
HBcore-specific T cells that were reduced by 3.9-fold in patients with severe hepatitis 
(Fig. S3). 
 
HBs-specific T cell dominance in CHB patients of differing age. 
We then analysed the composition and dominance of HBV-specific T cells and 
calculated, for individual patients with a detectable HBV-specific T cell response 
(164/189), the percentage of T cells recognizing the distinct HBV proteins (Fig 4). The 
bar graphs show the results of each individual patient (Fig 4A) and the pie charts 
display the median composition of HBV-specific T cells in patients of different age 
groups (Fig 4B). The percentage of HBs-specific T cells diminishes with age: whilst 
over 30-40% of HBV-specific T cells target HBs protein in patients aged 3-24 years, 
this is reduced to less than 10% in patients over the age of 35. Moreover, HBs-specific 
T cells constitute the dominant HBV-specific T cell response almost exclusively in 
under 25-year-olds, while it was never found to be dominant in patients over the age 
of 45. 
  
Characterisation of HBV-specific T cells in patients who resolved HBV infection 
after acute or chronic infection. 
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The influence that the duration of infection can exert on the HBV-specific T cell 
composition was then studied in two different populations with prior exposure to HBV. 
We collected PBMCs from patients who controlled HBV (anti-HBs positive and anti-
HBc positive) either after documented chronic infection (n=11, likely infected at birth 
and with at least >5 years clinically documented infection) or after an acute infection 
(n=27, HBsAg positive for <3 months). Importantly, the individuals in these two groups 
were age-matched. 
 
The majority of HBsAg-negative anti-HBc positive individuals with no history of CHB 
demonstrated, as expected, a robust expansion of HBV-specific T cells (22/27), and 
almost all (20/22) have T cells that recognize more than a single HBV protein (Fig 5A). 
Notably, HBs-specific T cells represent on average 33% of the total HBV-specific T 
cells detected and are the dominant response in 8/22 individuals (Fig 5B). This pattern 
was completely divergent from patients who became HBsAg negative after long-term 
CHB infection (Fig 5A, 5B, right panels). In these patients, HBV-specific T cell 
expansion was not only quantitatively lower, detected in fewer patients (6/11), and 
strikingly, no patient (0/11) demonstrated the presence of IFNγ producing HBs-specific 
T cells. These data show that even in HBsAg negative patients, the duration of prior 
HBV infection affects the antigenic profile of HBV-specific memory T cells. 
 
Lastly, we compared the median quantity of HBs-specific T cells (Fig 5C upper panel) 
and their median percentage among total HBV-specific T cells (Fig 5C lower panel) 
in all patients studied, subdivided by acute resolved and chronic resolved infection and 
by the age of CHB patients, thus consequently by the duration of HBV infection. Our 
data show that only during the first three decades of chronic infection, thus with 
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persistent HBsAg exposure, HBV-infected patients can still mount a HBs-specific T 
cell response, similar to that detected in patients who experienced transient short-term 
acute infection. However, in chronically infected patients above the age of 35, thus 
after long-term exposure to high quantity of HBsAg, the frequency and dominance of 





In this study, we first analysed the impact of HBsAg quantity on global T and NK cell 
phenotype and function. We did not find any direct experimental evidence linking 
HBsAg quantity with the suppression of global cellular immunity (T and NK cells). 
Different levels of HBsAg did not modulate proportionally the level of cytokines and 
cytotoxicity-associated molecules present in different T and NK cell subsets. Likewise, 
we did not observe any correlation with expression of several immunoregulatory 
receptors, including PD-1, CTLA-4, TIM-3, KLRG1, CD160, BTLA4 and TIGIT that 
have been shown to modulate the function of HBV-specific T cells. 
 
Our results are not unexpected. Despite global defects of NK and T cell function that 
have been reported in HBV infected patients29-31, these alterations were found in 
individuals with concomitant liver inflammation and are primarily caused (at least with 
regard to T cells) by arginine depletion30,31. When we subdivide the CHB patient cohort 
into patients with no, mild and severe hepatitis and compare them with healthy donors, 
we find a trend towards increased exhaustion/activation of T and NK cells linked with 
liver inflammation, but not with HBsAg levels (Fig. S4). Further supporting evidence 
that HBsAg does not affect global T cells is clear from our recent data, where we 
compared the immune gene expression profiles of multiple T and B cell subsets in 
age-matched healthy donors and CHB patients6. In order to detect differences induced 
only by HBV and not by liver inflammation, T and B cells were sorted from the blood 
of CHB patients in the HBeAg positive chronic infection phase, characterised by high 
levels of HBsAg and normal levels of transaminases. We could not find any significant 
alterations in the T cell compartment between CHB patients and healthy donors6. 
Finally, epidemiological data of CHB patients have never shown any evidence of 
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immunological defects. On the contrary, HBsAg presence has been linked to better 
control of malaria or increased maturation of general immunity in new-borns32, results 
that are clearly not compatible with the idea of HBsAg-mediated generic 
immunosuppression.   
 
We then characterized HBV-specific T cells, which are present at very low frequency 
in the blood of CHB patients and thus cannot influence the global T cell profile. 
Similarly, we did not find any evidence that HBsAg quantity could proportionally 
suppress the magnitude or multi-specificity of HBV-specific T cells. Conversely, to our 
surprise, we found that HBs-specific T cells were more likely to be detected in the 
blood of patients with higher levels of HBsAg. These findings, however should not be 
interpreted as a demonstration that HBsAg does not play a role in the modulation of 
anti-HBV immunity. On the contrary, when we analysed our results in relation to the 
age of the patients, which corresponds to the duration of infection, we find clear 
evidence, equally in CHB and in patients with resolved infection, that HBsAg 
persistence affects both the magnitude and dominance of their HBs-specific T cells. 
Importantly, only HBs-specific T cells declined with age, while T cells specific for the 
other HBV antigens persisted, and we confirm an increase of HBcore-specific T cell 
responses in HBeAg negative patients as observed by Park et al.27. Taken together, 
our results show that the impact of HBsAg on host immunity is not global but 
exclusively antigen-specific. Our data suggest that the duration of HBsAg exposure, 
more than the quantity of HBsAg-derived epitopes presented by hepatocytes or 
professional antigen presenting cells, has the ability to increasingly delete HBs-
specific T cells. Importantly, the progressive attrition of HBs-specific T cells in older 
patients detected in our study complements recent evidence from two other 
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independent groups showing, with different experimental procedures, the presence of 
only HBcore- and HBpol-specific T cells in adult HBeAg negative CHB patients10,11. 
The selective attrition of HBs-specific T cells and not of those specific for the other 
HBV antigens likely results from the prevailing expression of HBsAg. Although it 
declines with age, its overall expression is much higher than the other HBV antigens, 
and persists over time, as it is derived not only from infected hepatocytes, but also 
progressively from hepatocytes with HBV-DNA integration33. One other possibility is 
that the presence of HBcore- and HBpol-specific T cells remains, because of an 
increased immunogenicity at helper T cell level. It was demonstrated that HBcAg 
induced a much stronger helper T cell response than HBsAg in acute HBV patients34. 
However, a precise quantification of CD4 and CD8 T cells specific for the individual 
HBV antigens in different phases of CHB infection needs to be performed to confirm 
this hypothesis. 
 
A limitation of our study is the complete reliance on the circulating compartment, 
despite our acceptance that HBV-specific T cells can preferentially be localized in the 
liver35,36. Nevertheless, since there is no evidence demonstrating that intrahepatic 
recruitment is selective only for HBs- and not for HBcore- or HBpol-specific T cells or 
that it occurs only after a certain age, we believe that our cross-sectional data, 
analysing the peripheral compartment of patients, depicts a true progressive 
modification of the HBV-specific T cell repertoire. Certainly, a paired analysis of the 
global repertoire of HBV-specific T cell responses in blood and liver of patients at 
different ages would be ideal to confirm unequivocally our findings, but the quantity of 
intrahepatic lymphocytes necessary for such an analysis impose severe practical 
limitations. Moreover, the low frequency of HBV-specific T cells in CHB patients made 
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it necessary to expand them in vitro, which may not fully represent the in vivo 
frequency, yet quantifies T cells with proliferative and cytokine producing capacity, 
likely more relevant for biological function. 
 
We believe that our results can have important therapeutic implications. First, based 
on the lack of correlation between qHBsAg and global HBV-specific T cell immunity, 
we doubt that any reduction of serum HBsAg level, utilizing siRNA or antibodies 
specific for HBsAg, can trigger the restoration of HBV-specific immunity as often 
hypothesized17. Notwithstanding, we should consider that the modulation of HBsAg 
presentation induced by siRNA has clear kinetic differences in comparison to the one 
derived from the progressive and slow natural decline of HBsAg37. Thus, therapeutic 
strategies designed to recover the host’s ability to control HBV through a sharp 
reduction of HBV antigen production should be tested, but perhaps focusing on patient 
populations in the first three decades of life. Our data clearly show a disappearance 
of HBs-specific T cells relative to the increasing age of CHB patients, with a sharp 
decline in patients over the age of 35. 
 
Notably, whether HBV-specific T cells of younger CHB patients can be resuscitated 
by immunotherapy in vivo needs to be directly tested in clinical trials, and we are not 
suggesting that HBs-specific T cells are indispensable to HBV control. Our data show 
that some CHB patients became HBsAg negative despite a lack of detection of HBs-
specific T cells, indicating that we still lack a full understanding of the protective 
hierarchy of HBV-specific T cells. Nonetheless, our data show a clear progressive 
attrition of the multi-specificity of HBV-specific T cells over the duration of HBV 
infection, and we hypothesise that such progressive narrowing of the HBV-specific T 
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cell repertoire might reduce the chances of immunological control, which will have to 
be tested. 
 
We38 and others39 have already argued that targeting young CHB patients with 
immune therapies might have several advantages: better access of immune cells to 
infected hepatocytes40 due to their lower level of hepatic fibrosis, a liver environment 
without immunomodulatory cytokines present in chronic hepatitis41, and an earlier 
reduction of the level of HBV-DNA integration22. Although the presence of HBs-specific 
T cells might not be essential for the clearance of CHB infection in all patients, the 
impact that duration of HBV infection exerts on the breadth of HBV-specific T cells 
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Figure 1. Diagram of the experimental design and the clinical features of the 
patients studied 
(A) Number of patients analyzed for global T and NK cell immunity by mass cytometry 
(chronic HBV [CHB], n=48; upper section), and for antigen-specific T cell responses 
(CHB, n=189; acute resolved, n=27; chronic resolved, n=11, lower section). (B) Age 
distribution, HBsAg level and HBeAg status of 197 CHB patients. Upper-right insert 
shows correlation between patient age and HBsAg quantity. (C) Age and number of 
CHB patients studied (n=205) with different clinical and virological parameters, 
classified according to CPG (EASL 2017). (D) ALT levels and age of CHB patients 
(n=205) divided into patients with no (ALT <40 IU/mL), mild (ALT 40-80 IU/mL) and 
severe (ALT >80 IU/mL) hepatitis. Spearman correlation (B). 
 
Figure 2. Global T and NK cell profiling with CyTOF 
CyTOF data of PBMCs from 48 CHB patients (ex-vivo and after PMA/ionomycin 
stimulation*) were analyzed by UMAP and concatenated. (A) Delineation of 14 
different immune cell subsets based on the expression heatmaps of 40 markers (Fig 
S1A). (B) Concatenated UMAP plots of CHB patients with different levels of HBsAg. 
(C) Heatmap indicating the median frequency of 33 markers expressed by 20 immune 
cell subsets in patients with low (<1,000 IU/mL; n=14) and high (>10,000 IU/mL; n=13) 
levels of HBsAg. Correlation of indicated cytokines/chemokine (D) and exhaustion 
markers (E) expressed on CD4+ and CD8+ T cells with HBsAg levels (left panels), 
and bar graphs showing percentage of T cells expressing multiple 
cytokines/chemokines (D) or exhaustion markers (E) in patients with varying quantity 
of HBsAg. (F) Correlation of cytokines/chemokine and activation/inhibitory markers 
expressed on NK cells (left) and percentage of immature:mature NK cells (indicating 
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NK cell differentiation) in patients with varying levels of HBsAg (right). Spearman 
correlation (D, E, F). 
 
Figure 3. Quantity of HBV-specific T cells in relation to quantitative HBsAg and 
age 
(A) Quantity of T cells (spot forming units; SFU) specific for the whole HBV proteome 
(total) and the individual HBV proteins in CHB patient subgroups classified using EASL 
2017 CPG. Correlation analyses of HBsAg levels (B) or age (C) with the quantity of T 
cells specific for the whole HBV proteome, HBs-, HBcore-, HBpol- and HBx-protein. 
(D) Number of T cells specific for the indicated HBV-proteins in relation to age of the 
CHB patients. Each bar represents one patient. ANOVA with Kruskal-Wallis test (A); 
Spearman correlation (B, C). P<0.05 considered significant. 
 
Figure 4. Dominance of HBV-specific T cells in relation to age  
Composition of HBV-specific T cells in individual CHB patients with a detectable T cell 
response (164/189). (A) The percentage of HBV-specific T cells against HBs- (red), 
HBcore- (purple), HBpol- (green) and HBx-protein (blue) in each patient is shown. (B) 
Pie charts below show the median percentages of T cells specific for each HBV protein 
in different age-groups. 
 
Figure 5. Duration of infection affects the HBV-specific T cell profile 
(A) Quantity of HBV-specific T cells (spot forming units; SFU) in acute resolved, AR 
(n=27; left panel) and chronic resolved, CR (n=11; right panel) patients. Bars represent 
SFU per 10
5
 cells in response to indicated HBV proteins in each patient. Pie charts 
show the percentage of patients with HBV-specific T cells. (B) Composition of HBV-
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specific T cells in each patient. Pie charts show the mean percentages of T cells 
specific for the individual HBV proteins in both patient groups. (C) Quantity (SFU; 
upper panel) and frequency among total HBV-specific T cells (%; lower panel) of HBs-
specific T cells in the indicated categories of patients. Red lines indicate median. 
Statistical significance using acute resolved group as baseline was determined by 


















Number of patients 12 12 12 12 
HBsAg level (IU/mL): range 
(median)  
3394 – 365623 
(26665) 
21 – 32171 
(5418) 
75 – 38534 
(2462) 
2 – 17351 
(2113) 
HBsAg level (log10IU/mL): range 
(median) 
3.5 – 5.6 
(4.4) 
1.3 – 4.5 
(3.7) 
1.9 – 4.6 
(3.3) 
0.4 – 4.2 
(3.0) 
Age (years): range 
(median) 
24 – 47 
(31) 
20 – 51 
(35) 
24 – 60 
(41.5) 
22 – 57 
(50) 
Sex (male/female) 9/3 6/6 5/7 9/3 
ALT level (IU/L): range 
(median) 
36 – 298 
(99.5) 
15 – 165 
 (32.0) 
14 – 78 
 (22.5) 
17 – 67 
 (29.0) 
Median HBV-DNA level (log10IU/mL) 8.0 4.9 < 1.3 < 1.3 













RESOLVED Age (years): range 
(median) 
3 – 14 
(11.0) 
15 – 24 
(21.5) 
25 – 34 
(28.0) 
35 – 44 
(39.5) 
45 – 54 
(49.4) 
55 – 75 
(60.0) 
Number of patients 18 42 58 26 32 13 27 11 
Median age (years) 11 22 28 40 49 60 42 47 
HBsAg level (IU/ml): 
range (median)  
471 – 244,560 
(28,249) 
75 – 1,678,804 
(23,146) 
4 – 257,781 
(14,049) 
21 – 365,623 
(6,396) 
2 – 17,351 
(1,873) 
7 – 9,501 
(570) 
0 0 
HBsAg level (log10IU/ml):  
range (median) 
2.6 – 5.4 
(4.5) 
1.9 – 6.2 
(4.4) 
0.6 – 5.4 
(4.1) 
1.3 – 5.6 
(3.8) 
0.4 – 4.2 
(3.3) 





9 18 7 0 0 0 NA NA 
HBeAg+ chronic 
hepatitis 
2 12 16 4 5 0 NA NA 
HBeAg- chronic infection 7 9 13 5 1 13 NA NA 
HBeAg- chronic hepatitis 0 3 22 17 26 0 NA NA 
ALT level (IU/L): range 
(median) 
14 – 93 
(31.5) 
14 – 157 
 (36.0) 
11 – 539 
(36.5) 
14 – 565 
(30.0) 
14 – 666 
(36.5) 
13 – 1067 
(28.0) 
20 20 
Median HBV DNA level 
(log10IU/ml) 
5.73 8.19 5.15 3.04 3.28 3.05 < 1.3 < 1.3 
HBV genotype: 
A/B/C/D/E/unknown 
0/1/1/15/0/1 1/4/4/19/2/12 8/4/10/20/4/12 1/5/2/10/4/4 3/10/3/6/4/6 0/6/3/3/0/1 NA NA 
No treatment / NA 
therapy 
18/0 41/1 53/5 21/5 17/15 3/10 NA NA 
Sex (male/female) 5/13 21/21 31/27 21/5 24/8 6/7 unknown 10/1 
